Market Place
Sourcing Support
Verrica Pharma: Torii Files NDA for Molluscum Treatment in Japan
06 Dec 2024 //
GLOBENEWSWIRE
Verrica Announces Pricing of $42.0 Million Public Offering
21 Nov 2024 //
GLOBENEWSWIRE
Verrica Announces Proposed Public Offering
20 Nov 2024 //
GLOBENEWSWIRE
Verrica Pharma Reports Q3 2024 Results, Leadership Change
04 Nov 2024 //
GLOBENEWSWIRE
Verrica Announces Acceptance Of VP-315 Abstracts At Conference
24 Oct 2024 //
GLOBENEWSWIRE
Verrica Pharmaceuticals Restructures Commercial Organization
02 Oct 2024 //
GLOBENEWSWIRE
Verrica Pharma To Join H.C. Wainwright Investment Conference
04 Sep 2024 //
GLOBENEWSWIRE
Verrica Announces Positive Topline Results From Phase 2 Study Of VP-315 For BCC
14 Aug 2024 //
GLOBENEWSWIRE
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
14 Aug 2024 //
GLOBENEWSWIRE
Verrica Pharma To Report Q2 Results And VP-315 Trial Data
06 Aug 2024 //
GLOBENEWSWIRE
Verrica Pharmaceuticals Settles Litigation With Dormer Laboratories
01 Jul 2024 //
GLOBENEWSWIRE
Verrica At Jefferies Healthcare Conference In New York
30 May 2024 //
GLOBENEWSWIRE
Verrica Announces Torii Amendment To Fund YCANTH Warts Phase 3 Trial
15 May 2024 //
GLOBENEWSWIRE
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
13 May 2024 //
GLOBENEWSWIRE
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
09 May 2024 //
GLOBENEWSWIRE
Verrica Q1 2024 Results, Corporate Update On May 13
08 May 2024 //
GLOBENEWSWIRE
Verrica Announces Presentation at the Virtual Healthcare Conference
02 Apr 2024 //
GLOBENEWSWIRE
Verrica Announces that YCANTH Receives New Chemical Entity Status
26 Mar 2024 //
GLOBENEWSWIRE
Verrica Pharma Reports Fourth Quarter and Full-Year 2023 Financial Results
29 Feb 2024 //
GLOBENEWSWIRE
Verrica Announces Participation in TD Cowen 44th Annual Healthcare Conference
27 Feb 2024 //
GLOBENEWSWIRE
Verrica Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results
22 Feb 2024 //
GLOBENEWSWIRE
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer
05 Feb 2024 //
GLOBENEWSWIRE
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH
29 Jan 2024 //
GLOBENEWSWIRE
Verrica Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315
05 Jan 2024 //
GLOBENEWSWIRE
Verrica Announces Receipt of Minutes from Type C Meeting Regarding YCANTH
04 Jan 2024 //
GLOBENEWSWIRE
Verrica Announces Specialty Pharmacy Partnership Agreement with Walgreens
03 Jan 2024 //
GLOBENEWSWIRE
Torii Announces Positive Results from a Confirmatory Phase 3 Trial of TO-208
15 Dec 2023 //
GLOBENEWSWIRE
Verrica Announces Presentation at the Jefferies Global Healthcare Conference
10 Nov 2023 //
GLOBENEWSWIRE
Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Verrica Pharmaceuticals to and Report Third Quarter Financial Results
25 Oct 2023 //
GLOBENEWSWIRE
Verrica Pharma to Host Virtual KOL Event Discussing the Approval of YCANTH
27 Sep 2023 //
GLOBENEWSWIRE
Verrica Announces Participation in the H.C. Wainwright 25th Conference
31 Aug 2023 //
GLOBENEWSWIRE
Verrica Pharmaceuticals Announces First Sale of YCANTH„¢ to FFF Enterprises
24 Aug 2023 //
GLOBENEWSWIRE
Verrica Issues Statement in Support of FDA™s Warning Letters to Manufacturers
23 Aug 2023 //
GLOBENEWSWIRE
Verrica Announces Presentation of Lesion Clearance Data from an Ph 2 of VP-315
10 Aug 2023 //
GLOBENEWSWIRE
Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Verrica Announces Acceptance of Abstract Featuring Clinical Data of VP-315
03 Aug 2023 //
GLOBENEWSWIRE
Verrica Pharma Announces Closing of $125 Million Debt Financing with OrbiMed
26 Jul 2023 //
GLOBENEWSWIRE
Verrica`s drug gets US nod as first treatment for a type of skin infection
22 Jul 2023 //
REUTERS
Verrica Pharma Announces Presentation at the Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results
09 May 2023 //
GLOBENEWSWIRE
Verrica Announces Dosing of First Patient in Phase 2 Study Evaluating VP-315
12 Apr 2023 //
GLOBENEWSWIRE
Verrica Announces Presentation at 22nd Annual Needham Healthcare Conference
11 Apr 2023 //
GLOBENEWSWIRE
Verrica Pharma Reports Fourth Quarter and Full-Year 2022 Financial Results
06 Mar 2023 //
GLOBENEWSWIRE
Verrica Announces Participation at The Cowen 43rd Annual Health Care Conference
28 Feb 2023 //
GLOBENEWSWIRE
Verrica Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102
27 Feb 2023 //
GLOBENEWSWIRE
Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock
21 Feb 2023 //
GLOBENEWSWIRE
Verrica Announces Resubmission of New Drug Application for VP-102
24 Jan 2023 //
GLOBENEWSWIRE
Verrica Announces Transfer of Bulk Solution Manufacturing of VP-102 to Piramal
04 Jan 2023 //
GLOBENEWSWIRE
Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results
07 Nov 2022 //
GLOBENEWSWIRE
Two CRLs later, Illinois-based CDMO hit with FDA warning letter
05 Oct 2022 //
ENDPTS
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th
31 Aug 2022 //
GLOBENEWSWIRE
Verrica Pharma Starts PIII Trial of VP-102 for Molluscum Contagiosum
01 Aug 2022 //
GLOBENEWSWIRE
Verrica Announces Proposed Public Offering of Common Stock
29 Jun 2022 //
GLOBENEWSWIRE
Verrica Announces Pricing of Public Offering of Common Stock
29 Jun 2022 //
GLOBENEWSWIRE
Verrica Pharma Holds Type A Meeting for VP-102 for Molluscum Contagiosum
28 Jun 2022 //
GLOBENEWSWIRE
VRCA Investors Have Opportunity to Lead Verrica Pharma Securities Fraud Lawsuit
16 Jun 2022 //
PRNEWSWIRE
Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals
30 May 2022 //
LAWYER-MONTHLY
Verrica Down 64% as Molluscum Drug Gets CRL From FDA
26 May 2022 //
NASDAQ
